CD274 and non-small cell lung carcinoma: Notably, the efficacy and safety data of olomorasib (a second-generation KRASG12C inhibitor) in combination with pembrolizumab were recently presented at the World Conference on Lung Cancer 2024 conference.300 In this phase 1 trial, olomorasib was evaluated in combination with pembrolizumab and standard-of-care chemotherapy in treatment-naïve, KRASG12C-mutant NSCLC patients with any level of PD-L1 expression.